Physician profile
Jenna Horton
NPI 1689911869
$37,089.47
in general payments reported to CMS, 2019-2025
28 companies · $2,241 in 2025
The $2,241 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,364 · 2022: $20K · 2023: $6,224 · 2024: $1,430 · 2025: $2,241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,868 · Food and Beverage: $2,069 · Travel and Lodging: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,867.50 |
| Food and Beverage | $2,069.32 |
| Travel and Lodging | $958.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26,158.73 | 2021-2025 | |
| Allergan, INC. | $7,510.63 | 2021-2022 | |
| Astellas Pharma US INC | $504.39 | 2021-2023 | Myrbetriq |
| Sumitomo Pharma America, INC. | $476.07 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $343.69 | 2021-2022 | |
| Antares Pharma, INC. | $328.47 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Janssen Biotech, INC. | $286.83 | 2024-2025 | Erleada, Carvykti, Rybrevant |
| 180 Medical, INC. | $242.74 | 2021-2025 | Gentlecath |
| Pfizer INC. | $193.54 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $150.27 | 2021-2024 | Xiaflex, Aveed |
| Medtronic, INC. | $115.44 | 2021-2025 | Interstim |
| Merck Sharp & Dohme LLC | $94.29 | 2021-2023 | Keytruda, Welireg, Lynparza |
| Ferring Pharmaceuticals INC. | $93.46 | 2024-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $82.74 | 2021-2022 | |
| Hollister Incorporated | $69.64 | 2022-2023 | Infyna Chic |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $57.21 | 2022 | |
| Endo USA, INC. | $52.60 | 2024-2025 | Aveed, Xiaflex |
| Myriad Genetic Laboratories, INC. | $49.65 | 2021-2022 | |
| Blue Earth Diagnostics | $48.23 | 2021 | |
| Boston Scientific Corporation | $35.71 | 2022 | |
| Tolmar, INC. | $33.59 | 2023 | |
| Rochester Medical Corporation | $32.19 | 2021-2022 | |
| Urogen Pharma, INC. | $25.63 | 2023 | Jelmyto |
| Mission Pharmacal Company | $24.29 | 2021-2022 | |
| Halozyme INC | $22.92 | 2023 | |
| Alnylam Pharmaceuticals INC. | $21.89 | 2025 | Givlaari |
| Axonics, INC. | $18.31 | 2024 | Axonics |
| Dentsply Ih Ab | $16.32 | 2025 | Lofric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.